CQ coadministered with PQ — Competitive Intelligence Brief

CQ coadministered with PQ (CQ coadministered with PQ) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

phase 3 Antimalarial combination Plasmodium heme detoxification pathway; hypnozoite elimination Infectious Disease Small molecule

Target snapshot

CQ coadministered with PQ (CQ coadministered with PQ) — Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. CQ (chloroquine) and PQ (primaquine) work together as antimalarial agents that disrupt parasite metabolism and eliminate both blood and tissue stages of Plasmodium infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CQ coadministered with PQ TARGET	CQ coadministered with PQ	Fundação de Medicina Tropical Dr. Heitor Vieira Dourado	phase 3	Antimalarial combination	Plasmodium heme detoxification pathway; hypnozoite elimination
Tafenoquine plus DHA-Piperaquine	Tafenoquine plus DHA-Piperaquine	Menzies School of Health Research	marketed	Antimalarial combination	Plasmodium hypnozoites (tafenoquine); Plasmodium blood-stage parasites (DHA-piperaquine)
Tafenoquine plus Artesunate-pyronaridine	Tafenoquine plus Artesunate-pyronaridine	Menzies School of Health Research	marketed	Antimalarial combination	Plasmodium falciparum and Plasmodium vivax (parasite species); mechanism involves multiple targets including mitochondrial function and heme detoxification
artesunate-lapdap	artesunate-lapdap	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Plasmodium falciparum dihydrofolate reductase (lapdap component); artemisinin mechanism not fully elucidated but involves heme interaction
Sulfadoxine-pyrimethamine plus artesunate	Sulfadoxine-pyrimethamine plus artesunate	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Dihydrofolate reductase, dihydropteroate synthase (sulfadoxine-pyrimethamine); mitochondrial electron transport (artesunate)
Pyronaridine artesunate	Pyronaridine artesunate	Medicines for Malaria Venture	marketed	Antimalarial combination	Plasmodium falciparum DNA; heme detoxification pathway
artesunate-amodiaquine (AS-AQ)	artesunate-amodiaquine (AS-AQ)	Yale University	marketed	Artemisinin derivative + aminoquinoline antimalarial combination	Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class